Similar articles

• Protection of host from its own complement by membrane-bound complement inhibitors: C3 convertase inhibitors vs membrane attack complex inhibitors.

  Kinoshita T. Kinoshita T. Res Immunol. 1996 Feb;147(2):100-3. doi: 10.1016/0923-2494(96)87181-1. Res Immunol. 1996. PMID: 8792468 Review. No abstract available.
• Effect of epsilon-aminocaproylaminoacids on the activity of proteolytic enzymes.

  Bruzgo I, Midura-Nowaczek K, Roszkowska-Jakimiec W, Jasielczuk J. Bruzgo I, et al. Acta Pol Pharm. 2001 Mar-Apr;58(2):137-40. Acta Pol Pharm. 2001. PMID: 11501792
• Mice transgenic for human CD46 and CD55 are protected from human complement attack.

  Mulder LC, Mora M, Ciccopiedi E, Melli C, Nuti S, Marinucci G, Bruzzone P, Lazzeri M, Lorenzini R, Alfani D, et al. Mulder LC, et al. Transplant Proc. 1995 Feb;27(1):333-5. Transplant Proc. 1995. PMID: 7533403 No abstract available.
• Inhibition of the alternative pathway of complement by gold sodium thiomalate in vitro.

  Burge JJ, Fearon DT, Austen KF. Burge JJ, et al. J Immunol. 1978 May;120(5):1625-30. J Immunol. 1978. PMID: 659867 No abstract available.
• [Creation of synthetic serine proteinase inhibitors, an important pharmacological problem].

  Markwardt F. Markwardt F. Farmakol Toksikol. 1978 Sep-Oct;41(5):530-3. Farmakol Toksikol. 1978. PMID: 359347 Review. Russian. No abstract available.